Unilever has reached out to GlaxoSmithKline about taking advantage of a consumer partnership with Pfizer at a cost of £ 50bn which could be one of the biggest in the London market.
The real estate agency said on Saturday that it had “approached GSK and Pfizer for a business acquisition”. A valid request has not been made. GSK declined to comment.
“GSK Consumer Healthcare is at the forefront of consumer-oriented healthcare and can become more cohesive as Unilever continues to redefine its reputation. “There can be no guarantee that any agreement will be fulfilled,” Unilever added.
The Sunday Times, which first reported on the application, said Dove soap maker and Magnum ice cream offered about $ 50bn to share at the end of last year, but was turned down.
The researchers found that the business valued at around £ 47bn to £ 48bn, meaning that the investment did not include a large sum of money or savings from agreements between the two buying companies.
Unilever declined to comment on whether it would come back with more money.
GSK has been working to break down the divisions, alliances with Pfizer that make Panadol painkillers, Theraflu cold and cold medicine, and Otrivin decongestant. The new section will be led by inside Brian McNamara and its committee should be led by Dave Lewis, former Tesco CEO.
Advertisers including US hedge fund Elliott Management are putting pressure on Emma Walmsley, GSK CEO, to explore other options – including marketing – if they could bring significant benefits to their owners. Walmsley plans to use the proceeds from the spin-off to promote the drug and drug business.
Pfizer owns 32 per cent of the shares, which GSK has said it will list in London this year, although special groups are also looking at possible purchases.
The acquisition of Unilever could be one of the biggest in the London market, bringing in the third largest FTSE company with shares that, if independent, would be above 20. It could only be washed by Vodafone purchasing German Mannesmann in Germany. 1999 with AB InBev purchase of SABMiller in 2016.
The move came as Unilever, formerly one of the world’s largest corporations, sought to increase interest rates after a rapid growth in sales.
His share price has dropped since senior Alan Jope took office in 2019, as well as top 10 Investor Terry Smith this week. he attacked the company such as “working heavily with supervisors who are interested in and publicly displaying qualifications based on business requirements”.
Some vendors object to this, but many agree that the company should address its problem. It he agreed last year to sell his share of tea, which has been growing, for € 4.5bn going to a special CVC group, but still not making much profit under Jope.
Unilever in 2018 agreed to buy a nutritious beverage business at GSK, including the Horlicks brand, in India and other Asian markets for € 3.3bn. It has also found a variety of consumer health categories, including Smarty Pants, Olly and Onnit supplements and Liquid IV beverage mixtures.
Source link
